Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X:
“Ivonescimab (VEGF/PD1 bispecific) shows response rates of 65% in IMDC good risk RCC.
Single agent VEGF TKI is probably close to this activity, but it’s higher than single agent PD1 It’s likely combinations will be needed to clearly improve on existing 1st line options.”
You can also read:
LITESPARK-011 at ESMO 2026: Association Between HRQoL and Clinical Outcomes in Advanced RCC
